AstraZeneca

vorige Seite Seite 1 von 7 nächste Seite

Gepoolte Analyse von sieben klinischen Studien ergibt konstante Wirksamkeit von Ceftazidim-Avibactam bei der Behandlung von multiresistenten gramnegativen Bakterien

Diese Pressemitteilung wurde auf Englisch verfasst. Übersetzungen auf Deutsch, Französisch und Spanisch werden von PRNewswire für unsere internationalen Kunden zur Verfügung gestellt.

OTS0046
10.04.2016 14:58
 

Positive Phase-III-Ergebnisse für zwei Antibiotika, Zinforo(TM)? und Prüfpräparat Ceftazidime-avibactam, auf führendem Kongress für Infektionskrankheiten vorgestellt

Diese Pressemitteilung wurde auf Englisch verfasst. Übersetzungen auf Deutsch, Französisch und Spanisch werden von PRNewswire für unsere internationalen

OTS0015
27.04.2015 09:03
 

"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC

ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation

OTE0004
17.04.2015 16:33
 

Im New England Journal Of Medicine veröffentlichte Daten belegen, dass Naloxegol opioidbedingte Obstipation bei chronischen Schmerzpatienten verbessert

AstraZeneca hat heute bekannt gegeben, dass das New England Journal of Medicine (NEJM) Resultate zweier Phase III-Zulassungsstudien veröffentlicht hat - KODIAC-4 und KODIAC-5 zu Naloxegol, einem …

OTS0154
20.06.2014 22:30
 

Investigational Drug AZD9291 Shows Clinical Responses in Patients With Advanced NSCLC Who Have Previously Failed on Established EGFR TKIs

Data from the ongoing Phase I AURA study in patients with epidermal growth factor receptor mutation positive (EGFRm+), advanced non-small cell lung cancer (NSCLC), demonstrate that the overall disease …

OTE0003
31.05.2014 15:08
 

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast Cancer

FALCON (Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer) trial to compare fulvestrant to anastrozole (ARIMIDEX(R)) tablets in hormonal therapy-naïve, postmenopausal …

OTE0003
29.10.2012 13:05
 
OTE0016
26.03.2012 19:34
 

CAPRELSA? (vandetanib) Receives Positive CHMP Opinion in the European Union for Treating Advanced Medullary Thyroid Cancer

AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the …

OTE0007
18.11.2011 12:34
 

Study Suggests up to 135,000 Lives Could be Saved in Europe Each Year Through Better Control of Cardiovascular Risk Factors

Results from a large pan-European study suggest that up to 135,000 deaths from cardiovascular disease (CVD), such as heart attacks and strokes, could be prevented in Europe each year though better control …

OTE0004
15.04.2011 08:33
 

Study Shows Cardiovascular Deaths in Europe Could Be Prevented

Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year.[i] Results from a large pan-European study announced today indicate that many of …

OTE0004
08.11.2010 08:03
 

New JUPITER Analysis Demonstrates CRESTORTM (rosuvastatin) Significantly Reduces Major Cardiovascular Events in High Risk Patients

A post-hoc-analysis from JUPITER published in the European Heart Journal shows CRESTOR(TM) (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of …

OTE0013
22.10.2010 18:33
 

Final Analysis of Landmark IPASS Study Confirms That IRESSA (Gefitinib) is a Valuable Option for the First-Line Treatment of Patients With Advanced NSCLC With EGFR Activating Mutations

This press release has been made available on worldwide (excluding US) press communication media for the benefit of correspondents writing for the medical professional press.

OTE0006
11.10.2010 15:55
 

Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients

AstraZeneca's new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc. , significantly improved outcomes of patients with rheumatoid arthritis (RA) who responded …

OTE0006
22.09.2010 23:03
 
vorige Seite nächste Seite